Sugi Predict

Sugi Predict / Targets / TAOK3

TAOK3

Serine/threonine-protein kinase TAO3 · Q9H2K8 · TAOK3 on Sugi Atlas →

9,762 patent compounds predicted against TAOK3, 6,117 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL403002 SCHEMBL403002 0.61 5/20
SCHEMBL402544 SCHEMBL402544 0.58 5/20
SCHEMBL803222 SCHEMBL803222 0.48 5/20
SCHEMBL356087 SCHEMBL356087 0.60 4/20
SCHEMBL356088 SCHEMBL356088 0.60 4/20
SCHEMBL404935 SCHEMBL404935 0.50 4/20
SCHEMBL404115 SCHEMBL404115 0.47 4/20
SCHEMBL1095772 SCHEMBL1095772 0.47 4/20
Rasagiline Rasagiline (SCHEMBL934443) 0.47 4/20
SCHEMBL1095582 SCHEMBL1095582 0.42 4/20
SCHEMBL546548 SCHEMBL546548 0.57 3/20
SCHEMBL1109320 SCHEMBL1109320 0.52 3/20
SCHEMBL437450 SCHEMBL437450 0.48 3/20
SCHEMBL404732 SCHEMBL404732 0.48 3/20
SCHEMBL1057571 SCHEMBL1057571 0.48 3/20
SCHEMBL402511 SCHEMBL402511 0.47 3/20
SCHEMBL403836 SCHEMBL403836 0.46 3/20
SCHEMBL355014 SCHEMBL355014 0.45 3/20
SCHEMBL355015 SCHEMBL355015 0.45 3/20
SCHEMBL355780 SCHEMBL355780 0.45 3/20

Clinical trials — most relevant to TAOK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma PHASE2RECRUITING
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer PHASE1/PHASE2WITHDRAWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer PHASE2COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Does Protein Restriction Inhibit Prostrate Cancer Growth nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TAOK3 binder may also engage these)

ProteinNameSimilarity
Q9I9E0 — 1.000 Q9I9E0 →
Q8BYC6 — 1.000 Q8BYC6 →
Q53UA7 — 1.000 Q53UA7 →
Q7ZYJ0 — 1.000 Q7ZYJ0 →
Q6DD27 — 1.000 Q6DD27 →
Q5R4F3 — 1.000 Q5R4F3 →
O88664 — 1.000 O88664 →
Q5F2E8 — 1.000 Q5F2E8 →
TAOK1 Serine/threonine-protein kinase TAO1 1.000 landscape →
Q6NU21 — 0.999 Q6NU21 →
Q6GPK9 — 0.996 Q6GPK9 →
P46549 — 0.995 P46549 →
Q0KHQ5 — 0.992 Q0KHQ5 →
Q0IHQ8 — 0.987 Q0IHQ8 →
F1NBT0 — 0.987 F1NBT0 →
Q7SY52 — 0.987 Q7SY52 →
B7ZR30 — 0.985 B7ZR30 →
O55098 — 0.984 O55098 →
STK10 Serine/threonine-protein kinase 10 0.984 landscape →
E1BK52 — 0.983 E1BK52 →
E9PTG8 — 0.983 E9PTG8 →
CDC42BPA Serine/threonine-protein kinase MRCK alpha 0.981 landscape →
Q7SYB5 — 0.980 Q7SYB5 →
CDC42BPB Serine/threonine-protein kinase MRCK beta 0.980 landscape →
Q6A028 — 0.980 Q6A028 →
PTK2 Focal adhesion kinase 1 0.978 landscape →
O43295 — 0.978 O43295 →
O54874 — 0.978 O54874 →
Q6DFJ6 — 0.978 Q6DFJ6 →
Q5ZKI4 — 0.977 Q5ZKI4 →